CHOSA — Chosa Oncology AB Share News
0.000.00%
Last trade - 00:00- SEK65.48m
- SEK59.85m
- SEK0.00m
Brief: CHOSA Oncology AB Says Postpones Publication Of Interim Report Q4 2024
Brief: Chosa Oncology Carried Out Directed Issue Of Sek 1,55 Mln To Further Increase Business Development Activities
Brief: Chosa Oncology Announces Decision To Postpone Release Of Interim Report For Q2 2023
Brief: Chosa Oncology AB Publishes Results From Clinical Phase 2 Trial Of Liposomal Formulation In Breast Cancer, Using Predictive Marker For Cisplatin
Brief: Chosa Oncology Presents Clinical Phase 2 Results Of Liplacis And Its Drug Response Predictor Test
Brief: Chosa Oncology AB Announces Approved Re-Listing Memorandum
Brief: Chosa Oncology AB Initiates Payment Of Last Portion Of Loan Given To Rhovac AB
Founder Anders Ljungqvist Resigning From Board Due To Health Reasons
Brief: Rhovac AB Says Phase IIb Study In Prostate Cancer Failed To Meet Its Primary Endpoint
Brief: Canadian Intellectual Property Office Intends To Grant Rhovac's Patent Application For Rv001 (Onilcamotide) Cancer Vaccine
Brief: RhoVac AB Presents 3-Year Follow-Up Results Of The Phase I/II study In Prostate Cancer
Brief: RhoVac AB Confirms Previous Forecast To Be Able To Conclude Recruitment For Multi-Centre Bravac Phase IIb Study In Quarter 3 2021
Brief: RhoVac Says Global COVID-19 Vaccination Roll-Out Causes Delay To RhoVac's Phase IIb Study
Brief: Rhovac Q4 Pretax Result Swings To Loss Of SEK 15.2 Mln
Brief: Rhovac's Prostate Cancer Drug Candidate Is Granted Fast Track Designation By The FDA
Brief: RhoVac: Positive Results From Clinical Phase I/II Study Published In Journal Of Immunotherapy Of Cancer
Brief: Rhovac Q3 Pretax Loss Widens To SEK 12.9 Mln
Brief: RhoVac: COVID-19 Expected To Further Affect Clinical Phase IIb Study
Brief: Rhovac Q2 Pretax Loss Narrows To SEK 11.4 Million